Natera, Inc. (NASDAQ:NTRA) CFO Sells $540,007.71 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 4,983 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $108.37, for a total value of $540,007.71. Following the completion of the transaction, the chief financial officer now directly owns 75,059 shares in the company, valued at approximately $8,134,143.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, May 1st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The stock was sold at an average price of $93.97, for a total value of $175,348.02.
• On Monday, April 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $93.14, for a total transaction of $115,307.32.
• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The stock was sold at an average price of $89.55, for a total value of $63,132.75.
• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The stock was sold at an average price of $91.38, for a total value of $139,171.74.

Natera Stock Up 2.7 %

Shares of NTRA stock traded up $2.89 during trading hours on Tuesday, hitting $110.70. 1,114,651 shares of the company’s stock traded hands, compared to its average volume of 1,335,518. The company has a quick ratio of 3.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.36. The stock has a market cap of $13.59 billion, a price-to-earnings ratio of -35.48 and a beta of 1.48. The stock’s fifty day simple moving average is $105.29 and its two-hundred day simple moving average is $86.70. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $117.23.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The business had revenue of $367.70 million during the quarter, compared to analysts’ expectations of $316.31 million. During the same quarter in the previous year, the business earned ($1.23) earnings per share. The firm’s quarterly revenue was up 52.1% compared to the same quarter last year. On average, analysts expect that Natera, Inc. will post -2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Piper Sandler boosted their price target on Natera from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Tuesday, May 14th. Craig Hallum initiated coverage on Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 target price on the stock. Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target for the company in a research note on Friday, April 5th. Jefferies Financial Group assumed coverage on shares of Natera in a report on Monday, June 3rd. They issued a “buy” rating and a $142.00 price target on the stock. Finally, TD Cowen upped their price objective on shares of Natera from $123.00 to $137.00 and gave the stock a “buy” rating in a report on Friday, May 10th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $101.19.

Institutional Trading of Natera

Several institutional investors have recently bought and sold shares of the company. RiverPark Advisors LLC purchased a new position in Natera in the fourth quarter worth about $27,000. Principal Securities Inc. bought a new stake in shares of Natera during the fourth quarter valued at approximately $32,000. GAMMA Investing LLC raised its holdings in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares during the last quarter. YHB Investment Advisors Inc. bought a new position in Natera in the 1st quarter valued at approximately $36,000. Finally, Oliver Lagore Vanvalin Investment Group boosted its stake in Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 389 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.